AITRICS, a Korean medical AI startup, has closed a Series C funding round of $23.9 million (35 billion KRW), bringing together nine domestic and international venture capital firms and financial institutions.

The round included participation from existing investors Premier Partners, Han River Partners, Mirae Asset Venture Investment, and Shinyoung Securities–BSK Investment, alongside new investors KB Securities–Solidus Investment, SV Investment, and Mirae Asset Capital.

According to the company, this funding validates its differentiated technology, proven clinical utility, and global expansion potential. The capital will enhance core products including AITRICS-VC (VitalCare), which predicts patient deterioration in hospital settings, and V.Doc Pro, an AI copilot solution for medical professionals. Additional funds will support R&D for new product pipelines.

AITRICS is ramping up its international expansion. After establishing a Japanese subsidiary in March to build an operational foundation, the company plans to expand across Asia into Vietnam and Hong Kong. It also launched a U.S. entity in December 2023 to enter North America and is currently refining its global market strategy through collaboration with Mayo Clinic Platform.

“Thanks to the continued trust and support of many investors, we’ve reaffirmed our direction and growth potential,” said Kwangjun Kim, CEO of AITRICS. “Sustained investment from the same institutions shows our business strategy and products are consistently gaining recognition. This funding will enable us to steadily pursue our mid- to long-term strategy and significantly strengthen our growth and competitiveness.”

An SV Investment representative noted, “We decided to invest after confirming AITRICS’s innovative AI solutions, outstanding clinical results, and clear business strategy. This investment should accelerate expansion of clinical indications and global market entry, positioning AITRICS to become an essential AI solution provider in global healthcare settings.”

AITRICS previously raised $5.1 million (7.5 billion KRW) through seed and Series A rounds in 2017 and 2019, $2.4 million (3.5 billion KRW) in Pre-Series B in 2021, and $18.5 million (27.1 billion KRW) in Series B in 2024. With this Series C round, the company has secured cumulative funding of $49.9 million (73.1 billion KRW).